NCT05693519 (GICCA) is a clinical trial in Gastrointestinal Cancer, sponsored by Paul G. Kemps, MD.

Who is sponsoring NCT05693519?

NCT05693519 is sponsored by Paul G. Kemps, MD.

What condition does NCT05693519 study?

NCT05693519 studies Gastrointestinal Cancer, Colorectal Cancer, Gastric Cancer, Hepatoblastoma, Hepatocellular Carcinoma, Burkitt Lymphoma, Neuroendocrine Tumors.

Is NCT05693519 still recruiting?

NCT05693519 is currently status unknown. Last updated 23 January 2023.

Last reviewed 2023-01-23 · How we verify

NCT05693519: GICCA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GastroIntestinal Cancer in Children and Adolescents

Status unknown Last updated 23 January 2023

What this trial tests

trial in Gastrointestinal Cancer in 2,500 participants. Status unknown.

Timeline

22 December 2022

Primary endpoint
22 June 2023

22 June 2023

Quick facts

Lead sponsor	Paul G. Kemps, MD
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,500
Start date	22 December 2022
Primary completion	22 June 2023
Estimated completion	22 June 2023
Sites	2 locations across Netherlands

Conditions studied

Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →
Colorectal Cancer — all drugs for Colorectal Cancer →
Gastric Cancer — all drugs for Gastric Cancer →
Hepatoblastoma — all drugs for Hepatoblastoma →

Sponsor

Paul G. Kemps, MD

Who can join

Adults 0 to 24, any sex, with Gastrointestinal Cancer or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational population-based cohort study is to investigate the clinical characteristics and outcomes of children and adolescents with primary gastrointestinal malignancies registered in the publicly available Surveillance, Epidemiology, and End Results (SEER) 17 database during 2000-2019.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastrointestinal Cancer

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
NCT06936878 — BOLSTER: Learning New Skills to Thrive · NA · recruiting
NCT06864169 — A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) · Phase 2 · active not recruiting
NCT07056777 — Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastr · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05693519 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Paul G. Kemps, MD
Last refreshed: 23 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05693519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing